Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
UPDATE ON PHARMACOTHERAPY OF SYSTEMIC LUPUS-ERYTHEMATOSUS
Autore:
REDFORD TW; SMALL RE;
Indirizzi:
VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,SCH PHARM,POB 980533 RICHMOND VA 23298 VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,SCH PHARM RICHMOND VA 23298 UNIV IOWA,COLL PHARM IOWA CITY IA 52242
Titolo Testata:
American journal of health-system pharmacy
fascicolo: 23, volume: 52, anno: 1995,
pagine: 2686 - 2695
SICI:
1079-2082(1995)52:23<2686:UOPOSL>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
RHEUMATOID-ARTHRITIS; ASEPTIC-MENINGITIS; CONTROLLED TRIAL; RENAL-FUNCTION; PULSE THERAPY; RISK-FACTORS; NEPHRITIS; METHYLPREDNISOLONE; CYCLOPHOSPHAMIDE; HYDROXYCHLOROQUINE;
Keywords:
ANTIINFLAMMATORY AGENTS; ANTIMALARIAL AGENTS; DOSAGE; DOSAGE SCHEDULES; EPIDEMIOLOGY; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS; PLASMAPHERESIS; STEROIDS, CORTICO-; TOXICITY;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
119
Recensione:
Indirizzi per estratti:
Citazione:
T.W. Redford e R.E. Small, "UPDATE ON PHARMACOTHERAPY OF SYSTEMIC LUPUS-ERYTHEMATOSUS", American journal of health-system pharmacy, 52(23), 1995, pp. 2686-2695

Abstract

Established and novel approaches to the pharmacologic management of systemic lupus erythematosus (SLE) are described. SLE is a chronic, multiple-organ-system inflammatory disorder associated with immune systemdysfunction. Autoantibodies are produced that react with self-antigens, notably cell membranes and nuclear and cytoplasmic constituents. There are many clinical manifestations, including arthritis, arthralgia,myalgia, skin changes, photosensitivity reactions, fever, anemia, thrombocytopenia, proteinuria, and renal, CNS, and cardiopulmonary involvement. The disease characteristically fluctuates between remission andrelapse. Survival has been improving because of new drug treatments and better diagnostic and serologic tests. Minor manifestations can be treated with less toxic agents, such as nonsteroidal antiinflammatory drugs, sunscreens, topical and intralesional corticosteroids, and antimalarials. Aggressive therapy with high-dose corticosteroids or immunosuppressants is necessary in patients with worsening renal function (lupus nephritis). CNS lupus has responded to various degrees to dexamethasone, methylprednisolone, and cyclophosphamide. Other therapeutic options include methotrexate in corticosteroid-resistant SLE and cyclosporine. The use of monoclonal antibodies is under intensive study. As mortality due to SLE decreases, complications like cardiovascular problems are becoming more prominent; patients may require antihypertensives, cholesterol-lowering drugs, and hypoglycemic agents. The complexityand chronicity of SLE have led to diverse pharmacotherapeutic strategies based on the organ systems involved. Immunologic research may ultimately bring patients greater relief.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 07/07/20 alle ore 20:07:49